Sanofi faces U.S. lawsuit over failed obesity drug
NEW YORK Nov 13 (Reuters) - Sanofi-Aventis SA (SASY.PA) faces a lawsuit alleging the French drugmaker misled investors about prospects for its obesity drug Acomplia, known as Zimulti in the United States.
Law firm Coughlin Stoia Geller Rudman & Robbins LLP said on Tuesday it had commenced action on behalf of an institutional investor in the U.S. District Court for the Southern District of New York.
Acomplia had been touted as a potential blockbuster by Sanofi, the world's third largest drugmaker, but was rejected by a U.S. regulatory committee in June 2007.
The complaint charges that Sanofi statements about the drug were materially false and misleading because the company concealed data about the drug's propensity to cause depression.
(Reporting by Ben Hirschler)
((Editing by Richard Chang; email@example.com; +44 7771 575 829; Reuters Messaging: firstname.lastname@example.org)) Keywords: SANOFI LAWSUIT/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2311
- Israel warns of long Gaza war as Palestinian fighters cross border |
- West agrees wider Russia sanctions as Kiev says forces near crash site
- Court orders Russia to pay $50 billion for seizing Yukos assets |
- Man found dead trapped between elevator and shaft wall in NYC
- Wall Street yawns as deal news offsets data; Herbalife sinks